Burlingame, CA – November 8, 2012 – GLYSENS INCORPORATED presented results today of the recently completed first human feasibility trial of its long term, fully implantable continuous glucose monitoring (ICGM) system.  The trial evaluated the Company’s first generation fully-implanted sensors in six individuals with diabetes for periods of five to six months.

The presentation, entitled “Application of the Implantable Continuous Glucose Monitoring System in a Human Subject” was delivered by GlySens’s President and CEO Dr. Joseph Lucisano at a morning session of the twelfth annual meeting of the Diabetes Technology Society. The annual meeting, held this year November 8-10 at the Bethesda North Marriott Hotel & Conference Center, is a premier scientific venue for discussion of diabetes care technology. Last year’s meeting brought together over 500 clinicians and scientists from 24 countries to focus on applying science and technology to improve the lives of people with diabetes.